Stockreport
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets. Management has guided for over $250m revenues in 2024, and over $700m by 2028 thanks to the launch of a new dermal filler range of products. Smartly marketed, effective, and growing market share, Jeuveau seems a strong product, and with support from the new range, I'd argue Evolus is well placed to grow its valuation and share price over the next several years. Investment Overview Evolus ( NASDAQ: EOLS ) went public in February 2018, its initial public offering ("IPO") raising ~$60m in gross proceeds, at a price of $12 per share. The company describes itself as "global performance beauty company with a customer-centric approach to delivering breakthrough products", in its 2023 annual report/ 10K submission , and it
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | EOLS | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EOLS alerts
EOLS alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
NEWS
NEWS
- Evolus to Report First Quarter Financial Results on May 7, 2024[Business Wire]
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau® [Yahoo! Finance][Yahoo! Finance]
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®[Business Wire]
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN][CNN]
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN][CNN]
- More
EOLS
SEC Filings
SEC Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- EOLS's page on the SEC website
- More